Author: Schaeffer, Michael ; Isner-Horobeti, Marie-Eve ; Vautravers, Philippe ; Dupeyron, Arnaud ; Sauleau, Erik ; Dufour, Stéphane Pascal ; Lecocq, Jehan

OBJECTIVEThis study compared the effects of high-force versus low-force lumbar traction in the treatment of acute lumbar sciatica secondary to disc herniation.METHODSA randomized double blind trial was performed, and 17 subjects with acute lumbar sciatica secondary to disc herniation were assigned to high-force traction at 50% body weight (BW; LT50, n = 8) or low force traction at 10% BW (LT10, n = 9) for 10 sessions in 2 weeks. Radicular pain (visual analogue scale [VAS]), lumbo-pelvic-hip complex motion (finger-to-toe test), lumbar-spine mobility (Schöber-Macrae test), nerve root compression (straight-leg-raising test), disability (EIFEL score), drug consumption, and overall evaluation of each patient were measured at days 0, 7, 1, 4, and 28.RESULTSSignificant (P < .05) improvements were observed in the LT50 and LT10 groups, respectively, between day 0 and day 14 (end of treatment) for VAS (-44% and -36%), EIFEL score (-43% and -28%) and overall patient evaluation (+3.1 and +2.0 points). At that time, LT50 specifically improved in the finger-to-toe test (-42%), the straight-leg-raising test (+58), and drug consumption (-50%). No significant interaction effect (group-by-time) was revealed, and the effect of traction treatment was independent of the level of medication. During the 2-week follow-up at day 28, only the LT10 group improved (P < .05) in VAS (-52%) and EIFEL scores (-46%). During this period, no interaction effect (group-by-time) was identified, and the observed responses were independent of the level of medication.CONCLUSIONSFor this preliminary study, patients with acute lumbar sciatica secondary to disc herniation who received 2 weeks of lumbar traction reported reduced radicular pain and functional impairment and improved well-being regardless of the traction force group to which they were assigned. The effects of the traction treatment were independent of the initial level of medication and appeared to be maintained at the 2-week follow-up.

01 May 2002·Journal of natural toxins

Restoration of nerve growth factor in organs of mice injected with cobra venom followed by specific treatment and reversal period.

Article

Author: Lipps, Binie V

Research from this laboratory reported the decreased levels of endogenously present nerve growth factor (NGF) in organs of mice as a consequence of sub-lethal injection of Naja kaouthia venom. This research reports that the decreased levels of NGF in organs of mice were prevented by (1) specific treatment and (2) restored to normal by a prolonged period. Adult female Balb/c mice were injected intramuscularly (IM) with a sub-lethal dose of cobra venom. The injected mice were divided into five groups. Mice in group I were injected with PBS, group II with anti-cobra venom, and group III with lethal toxin neutralizing factor (LTNF). Mice in group IV were treated IM with synthetic LTNF (LT-10), and mice in group V were treated orally with LT-10. After 24 hr. mice were sacrificed and NGF levels in organ homogenates were assayed and compared with control mice not injected with venom. It was observed that the organs from group I treated with PBS showed a tremendous drop in NGF level in comparison to the organs of the control mice. It was further revealed that the decreased levels of NGF in organs of injected mice were prevented by treatment with anti-cobra venom, LTNF and LT-10 by IM, or oral routes. In the second series of experiments, mice injected with sub-lethal dose of cobra venom were sacrificed after 1, 3, 7, and 10 days, and the organs were assayed for NGF levels. It was observed that the recovery period for normal homeostasis of NGF was between 7 and 10 days in the brain, heart, liver, salivary glands, and ovaries.

Metabolites

PPAR Signaling Maintains Metabolic Homeostasis under Hypothermia in Freshwater Drum (Aplodinotus grunniens)

Article

Author: Xue, Miaomiao ; Xu, Pao ; Wang, Meiyao ; Wu, Ningyuan ; Wen, Haibo ; Song, Changyou ; Li, Jianlin ; Li, Hongxia ; Chen, Jianxiang

Aplodinotus grunniens, known as freshwater drum, is a kind of eurythermal freshwater fish that is widely distributed in North America. In 2019, our research group reached a milestone on its artificial breeding and cultivation and have investigated its physiological adaption to the environment, providing a breakthrough and prospects for aquaculture. However, its adaptability and metabolic homeostasis to hypothermia is not fully understood. In this experiment, cold stress was conducted at 18 °C (LT18) and 10 °C (LT10) with 25 °C as control (Con) for 8 days to explore the effects of short-term hypothermia on the physiology and metabolism of freshwater drum. From the results, the level of free essential amino acids in LT18 and LT10 decreased significantly after 2 days cold stress compared with Con. Furthermore, plasma total triglyceride (TG) content and lipase (LPS) activity were decreased at LT10 for 2d. With RNA-seq in the liver, metabolic-related signaling, especially amino acid synthesis and lipid metabolism, was inhibited by hypothermia. Specifically, the PPAR signaling pathway is correlated with the inhibition of lipid and amino acid metabolism induced by hypothermia. These data confirmed that PPAR signaling maintains lipid and amino acid metabolic homeostasis during cold stress. These results give a theoretical foundation for hypothermia resistance in the area of metabolic homeostasis for freshwater drum.

100 Deals associated with LT-010

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	Preclinical	CN	Chengdu Lingtai Krypton Biotechnology Co., Ltd	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

LT-010

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation